Trial Profile
A Phase II Study of VEGF Trap (NSC 724770) In Patients With MDS.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Myelodysplastic syndromes
- Focus Biomarker; Therapeutic Use
- 20 Nov 2012 Status changed from completed to recruiting as reported by ClinicalTrials.gov record.
- 14 Jun 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
- 14 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.